More than a year has passed since Humira biosimilars were launched in the US, and with these, several other biosimilar drug approvals that either directly compete with Humira or are indicated for other rare immunologic conditions, macular degeneration, and oncology and hematological disease.  Ongoing industry surveillance of biosimilars and the   Source: “Biosimilars are becoming more widely available,…

Learn more about what PurpleLab can do for Commercial Pharma Life Sciences Download

We provide a real-world data lab to accelerate the discovery and adoption of healthcare innovations. From life science companies, hospitals and health plans to agencies and advertising technology companies, PurpleLab is your trusted real-world-data partner.  Life Sciences Download Let’s Talk! Previous Next

An Antidote to Long-Standing Care and Cost Outcomes Analysis Frustrations Life Sciences Download

PurpleLab’s® Provider Data is the foundation of our simple to use provider data analytics solutions. This single source of truth provides healthcare organizations with the most comprehensive and up to date provider information Life Sciences Download Let’s Talk! Previous Next

PurpleLab Accelerates Clinical Trial Lifecycle with Real-World-Data This video was created in collaboration with the Applied Clinical Trials. Approximately 80% of clinical trials will face delays at some point in the trial process. Jason Gagner talked with ACT about how PurpleLab uses real-world data to better inform trials and improve their success rates. Learn More About: Utilizing…

This study was run to determine if a racial disparity exists in biomarker testing for NSCLC (non-small cell lung cancer) patients. Jared Safran, PharmD, MS, Russell Robbins, MD, MBA, Maggie Mendes, Douglas Londono, PhD, Grace Kane, MS. Healthcare is evolving into precision medicine or what the FDA refers to as personalized medicine1. This targeted approach…

PurpleLab’s® Clinical Trial data provides detailed metrics on clinical trial activities performed by healthcare providers (HCPs) and healthcare organizations (HCOs). By integrating clinical trial data, overall profiles of HCPs and HCOs are enhanced, offering a clearer view of a provider’s clinical research experience. With this added visibility, users can efficiently segment and identify potential investigators and…

This study was run to evaluate whether provider specialty is a driver for biosimilar adoption, defined as adoption probability difference (APD). Diane Faraone, PharmD, Russell Robbins, MD, MBA, Grace Kane, MS, Douglas Londono, PhD.  The US biologics market has significantly expanded in recent years; projected to reach $62 billion in prescription drug spend by 2025. Biosimilar…